Advaxis Presents Preliminary Data From a Phase 1/2 Trial of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients

PRINCETON, N.J., March 16, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage cancer immunotherapy company, presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have completed treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 – 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea.

The data were highlighted in an oral presentation by Kimberly Perez, M.D., Assistant Professor of Medicine at the Alpert Medical School, Brown University, during the recent International Anal Neoplasia Society (IANS) Scientific Meeting 2015, in Atlanta, Georgia.

Dr. Perez stated, "Though preliminary, the data we have observed thus far are extremely encouraging as all treated patients enrolled since April 2013 have had a complete response with no recurrence of the cancer. ADXS-HPV has the potential to be an important advancement in the treatment of HPV-associated anal cancer, and we look forward to reporting the full safety and efficacy data set once all 25 patients have completed the dosing regimen."

BrUOG 276 (ClinicalTrials.gov Identifier: NCT01671488) is a Phase 1/2 non-randomized, open-label, multi-center study being conducted by the Brown University Oncology Group with financial support from The Farrah Fawcett Foundation. The study is designed to determine the safety and effectiveness of ADXS-HPV when combined with standard chemotherapy and radiation treatment for locally advanced anal cancer in approximately 25 patients who have a high risk of recurrence based on their disease characteristics.  The primary efficacy objective of the study is to assess the proportion of patients maintaining a clinical complete response at the 6-month mark.   

David J. Mauro, M.D., Ph.D., Chief Medical Officer of Advaxis stated, "We are very pleased with the preliminary data from this Phase 1/2 study of ADXS-HPV in HPV-associated anal cancer as it adds to the encouraging data that we have observed in our additional ADXS-HPV programs and across our broader Lm -LLO cancer immunotherapy portfolio. We look forward to reviewing the full data set from this trial in support of the continued clinical development of ADXS-HPV in HPV-associated anal cancer."

About HPV and Anal Cancer

According to the American Cancer Society, most squamous cell anal cancers seem to be linked to infection by the human papilloma virus (HPV), the same virus that causes cervical cancer. In fact, women with a history of cervical cancer (or pre-cancer) have an increased risk of anal cancer. Anal cancer is fairly rare – much less common than cancer of the colon or rectum. About 7,210 new cases will be diagnosed and about 950 people are expected to die of anal cancer in the United States during 2014.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm -LLO platform technology. The Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm -LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm -LLO cancer immunotherapy, ADXS-PSA, with Merck's PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm -LLO immunotherapy ADXS-HER2, to target the HER2 receptor expressing cancers. HER2 is expressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-HER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-HER2 for both human and animal-health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis has licensed ADXS-HER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information about our cancer immunotherapies please visit www.advaxis.com .

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS-HPV. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

KEYTRUDA is a registered trademark of Merck & Co., Inc.

Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO 609.452.9813 ext. 102 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Childcare Scale Makes Its Case, With Caveats Attached

Updated Category News Views 58

Childcare’s math is brutal before anybody starts arguing over ownership. Families need dependable hours, educators deserve better pay, and operators must keep buildings safe, staffed and open without pricing working parents clean out of the market. That is why this new Tyton Partners review of multi-site providers deserves a fair look, even if nobody should mistake a...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading

Top 5 Most Recently Viewed Articles

Freddie Mac's 30-Year Mortgage Rate Decreases Slightly

Updated Category News Views 219

Freddie Mac Reports on Mortgage Rates In recent reports from Freddie Mac, there's good news for potential homebuyers. The 30-year fixed-rate mortgage (FRM) has seen a slight decline, which is a welcome change in a fluctuating market. This current value sits at an average of 6.64%, reflecting a small drop from the previous week's average of 6.65%. Understanding the Current...

Continue Reading
Sports.com Partners with SEGG Media for Soccerex Event

Updated Category News Views 251

Sports.com Joins SEGG Media as Title Sponsor at Soccerex Miami 2025 MIAMI BEACH, Fla. — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) has officially announced that Sports.com will take on the role of Title Sponsor for the engaging Soccerex Miami event happening at the Miami Beach Convention Center. This sponsorship reflects a significant commitment to promoting...

Continue Reading
Gastech 2025: A Global Convergence for Energy Innovations

Updated Category News Views 249

Gastech 2025 Unites the World of Energy Innovation Gastech 2025 welcomes more than 50,000 attendees from over 150 countries, establishing Milan as the global center for critical dialogues on energy supply, transformation, and innovation. This event has become a vital platform for high-level conversations that shape the future of energy. Leadership at Gastech 2025...

Continue Reading
Baird Confirms Outperform Rating for Costco Amidst Strong Growth

Updated Category News Views 68

Strong Sales Performance Driving Costco's Success Baird has reaffirmed its Outperform rating for Costco Wholesale (NASDAQ: COST), while upholding a price target of $975. The firm's latest insights indicate that Costco's global core comparable sales, excluding gas and foreign exchange influences, have surged by 8.9%. Such a rise is significant and demonstrates the...

Continue Reading
Celebrating a Decade of DNBSEQ™: Innovations and Impact

Updated Category News Views 290

Celebrating a Decade of DNBSEQ™ Technology MGI Tech Co., Ltd. (NASDAQ: MGI) is thrilled to celebrate ten years of its revolutionary DNBSEQ™ sequencing technology. This milestone marks a significant journey in transforming the landscape of genomics, offering solutions that not only enhance scientific research but also make genomic information more accessible to a...

Continue Reading